Navigation Links
Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study
Date:9/13/2007

SIMPLIFI to Examine Single-Dose and Infrequent-Dosing Regimens in cSSSI

CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Targanta Therapeutics Corporation today announced the initiation of its Phase 2 trial investigating the safety and efficacy of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI. Oritavancin is Targanta's lead antibiotic candidate targeting gram- positive infections.

This Phase 2 study is an international, multi-center, randomized, double- blind, controlled study in patients with cSSSI presumed or proven to be caused by gram-positive pathogen(s). The study consists of three treatment arms in which patients will receive either:

-- 200 mg oritavancin IV daily for a minimum of 3 days and up to a maximum

of 7 days (the dosing regimen used in the larger of the two completed

Phase 3 studies of oritavancin in cSSSI);

-- A single dose of 1200 mg oritavancin IV; or

-- A single dose of 800 mg oritavancin IV, with a further dose of 400 mg

IV on Day 5 if needed.

As its primary endpoint, SIMPLIFI will measure clinical response (either cure or improvement versus failure) in clinically evaluable patients. As a secondary endpoint, this study will examine safety data in all intent-to-treat patients. Targanta expects to enroll a total of 300 patients in this study.

"Based on extensive pharmacokinetic and pharmacodynamic modeling, we believe there is a high likelihood of success with the less frequent oritavancin dosing regimens being studied here," said Pierre E. G. Etienne, M.D. Chief Development Officer of Targanta. "We currently expect to complete collection of clinical trial data from SIMPLIFI in the second half of 2008, at which time we will assess the outcomes and determine whether to pursue Phase 3 registration trials. In the meantime, we are working on the preparation of our first U.S. and European regulatory s
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/10/2014)... , July 11, 2014  Major advances ... of cancer are being highlighted in a three-day ... from 10-12 July, 2014.  Renowned national and ... share best practices and exchange knowledge on modern ... accurate and efficient. The Summit ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... LA JOLLA, Calif., Feb. 1, 2011 Transdel ... ), a specialty pharmaceutical company focused on developing ... today announced that the Company has been exploring strategic ... banks, American MedTech Advisors and ESC Advisors, a ...
... Feb. 1, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS ... lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also ... two years, we have progressed the GALNS program from ...
Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA 2BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA 3BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA 4
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
(Date:7/11/2014)... HOUSTON (July 10, 2014) Obese and ... from their health care providers, according to new ... Center at Houston (UTHealth). , National guidelines state ... on the importance of maintaining a healthy weight. ... events are the leading cause of line-of-duty deaths ...
(Date:7/11/2014)... (HealthDay News) -- Prostate cancer patients are more likely ... treatment and die sooner if they also have depression, ... more than 41,200 American men who were diagnosed with ... them through 2009. Nearly 1,900 of the patients had ... their prostate cancer was discovered. "Men with intermediate- ...
(Date:7/11/2014)... Europe is one of the largest ... hence, irrigated land area. The agricultural sector is a ... around 30.0% of the total water use. The scale ... southern region, but far from negligible in most northern ... over 60.0% of the water use in most countries, ...
(Date:7/11/2014)... a history of hazardous or binge drinking reduced their ... mobile phone text messages following a visit to the ... in Annals of Emergency Medicine (" A ... Patients: A Randomized Clinical Trial "). , "Each day ... to 24 visit ERs and up to half have ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Depression May Make It Harder to Beat Prostate Cancer 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Text message medicine: Texts from the ER can reduce binge drinking 2
... men who smoke had less risk of undergoing total joint ... that men who were overweight, or who engaged in vigorous ... this study are now available in Arthritis & Rheumatism ... College of Rheumatology (ACR). Research has shown that ...
... , THURSDAY, July 7 (HealthDay News) -- Suicide ... financial crisis, while road deaths decreased, according to researchers. ... percent relative increase) between 2007 and 2009. At the same ... in suicide rates seen in EU countries before 2007. ...
... belief, so-called hypoallergenic dogs do not have lower household allergen ... study by Henry Ford Hospital researchers who sought to evaluate ... home than other dogs. Hypoallergenic dogs are believed to produce ... findings are to be published online this month in the ...
... and treatment of pediatric leukemia at St. Jude Children,s Research ... M. Stratton Medal from the American Society of Hematology (ASH). ... fight against this blood cancer during the past three decades. ... of Grune and Stratton, the medical publishing house that first ...
... be reached in time to avert an unprecedented suspension of ... Medicaid and other federal health programs," Virginia Hood, MBBS, ... told the president, vice president and Congressional leaders today. ... legislation to increase the debt ceiling linked to an agreement ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, July ... dignity therapy helped terminally ill patients improve their quality ... changing how their family sees and appreciates them, according ... however, ease those distressed by dying, as the researchers ...
Cached Medicine News:Health News:Male smokers less likely to need joint replacement surgery of hip or knee 2Health News:Europe's Suicides Up, Road Deaths Down After Economy Tanked 2Health News:Study: Hypoallergenic dogs not less allergic than other dogs 2Health News:Ching-Hon Pui, M.D., honored by the American Society of Hematology for work in childhood cancer 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 3Health News:Special Talk Therapy Seems to Help Dying Patients 2Health News:Special Talk Therapy Seems to Help Dying Patients 3
... 10.1 kg, Interior Dimensions (WxDxH): 31.1 x ... (WxDxH): 44.6 x 22.4 x 20.5 cm, ... 2 - 300 x 35 mm bottles, ... or 1 - 240 x 80 mm ...
... four basic components: sample well plate, filter support ... diagram). The sample well plate is available in ... (see below). All three plates are interchangeable and ... conjunction with a complete system. The tension on ...
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
Medicine Products: